文献速递血管炎

生物制剂治疗复发性和/或难治性嗜酸性肉芽肿性多血管炎:欧洲协作研究

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.
PubMed 文献 · Arthritis Rheumatol · 2021-01-23

这项欧洲回顾性协作研究纳入147例接受生物制剂治疗的难治性/复发性EGPA患者,其中63例用利妥昔单抗、51例用美泊利珠单抗、33例用奥马珠单抗。结果显示利妥昔单抗对EGPA血管炎复发有效,美泊利珠单抗对糖皮质激素依赖性哮喘高效且安全性好,100mg每月可能是可接受的一线剂量。

要点

  • 利妥昔单抗组中位BVAS从8.5降至6个月1和12个月0,缓解率49%。
  • 美泊利珠单抗组缓解率78%、部分反应10%、治疗失败8%,显著优于奥马珠单抗组。
  • 美泊利珠单抗100mg与300mg组12个月缓解率分别为76%和82%。

核心结论

  • 利妥昔单抗可能有效治疗EGPA血管炎复发。
  • 美泊利珠单抗对糖皮质激素依赖性哮喘高效且安全性好。
  • 100mg每月美泊利珠单抗可能是特定情况下可接受的一线剂量。

研究设计与样本

  • 欧洲回顾性协作研究,纳入147例接受生物制剂治疗的难治性和/或复发性EGPA患者。

主要发现

  • 利妥昔单抗组中位BVAS从8.5降至6个月1和12个月0。
  • 利妥昔单抗组缓解率49%、部分反应24%、治疗失败24%、因不良事件停药3%。
  • 奥马珠单抗组缓解率15%、部分反应33%、治疗失败48%、因不良事件停药4%。
  • 美泊利珠单抗组缓解率78%、部分反应10%、治疗失败8%、因不良事件停药4%。
  • 美泊利珠单抗100mg和300mg组12个月缓解率分别为76%和82%。

关键数值与推荐

  • 利妥昔单抗组中位BVAS为8.5(IQR 5-13),奥马珠单抗组为2(IQR 1-4.5),美泊利珠单抗组为2(IQR 1-5)。
  • 利妥昔单抗组6个月中位BVAS为1(IQR 0-4.5),12个月为0(IQR 0-2)。
  • 美泊利珠单抗对糖皮质激素依赖性哮喘的保激素效应和总体反应优于奥马珠单抗。

临床怎么用

  • 利妥昔单抗可用于EGPA血管炎复发的治疗。
  • 美泊利珠单抗可用于糖皮质激素依赖性哮喘的EGPA患者。
  • 特定情况下可考虑100mg每月美泊利珠单抗作为一线治疗,但需注意未与300mg每月验证剂量比较。

局限性

  • 回顾性研究设计。
  • 100mg美泊利珠单抗未与300mg每月验证剂量进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS: Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was 2 (IQR 1-5). In patients receiving RTX, the median BVAS declined both at 6 months (median 1, IQR 0-4.5) and at 12 months (median 0, IQR 0-2), and the frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 49%, 24%, 24%, and 3%, respectively. For the treatment of glucocorticoid (GC)-dependent asthma, patients who received MEPO had a much better GC-sparing effect and overall response than did patients who received OMA. The frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 15%, 33%, 48%, and 4%, respectively, in the OMA group and 78%, 10%, 8%, and 4%, respectively, in the MEPO group. Remission rates at 12 months were 76% and 82% among patients receiving MEPO at a doses of 100 mg and 300 mg, respectively. CONCLUSION: These results suggest that RTX could be effective in treating relapses of EGPA vasculitis. MEPO is highly effective with a good safety profile in patients with GC-dependent asthma. Our data suggest that 100 mg MEPO monthly could be an acceptable dosage for first-line therapy in selected instances of EGPA, recognizing, however, that this has not been compared to the validated dosage of 300 mg monthly.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Canzian A, Venhoff N, Urban ML, et al. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. Arthritis Rheumatol. 2021. PMID: 33001543. doi:10.1002/art.41534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。